The sustained GM-CSF release by injected tumor cells can paradoxically lead to disease progression due to the provocation of immune tolerance via the differentiation of tolerogenic DCs and the recruitment of myeloid suppressor cells [53–55]. This evidence concerns the gene CSF2 and neoplasm.